Delivery Order SPE2DB20D3101-SPE2DB22FQVA7

Award Date 9/15/22
Potential Completion Date 9/16/22
Potential Value $4.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of LANTUS SOLOSTAR 100 UNIT/ML 3ML, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $2,837.69 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, under a larger $999,999,999 Indefinite Delivery Contract (IDC) the company holds with the DLA Troop Support Medical. This single-award IDC serves as the primary vehicle for AmerisourceBergen to supply a...
This federal contract award is for the delivery of LANTUS SOLOSTAR 100 UNIT/ML 3ML, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $2,369.16 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on March 21, 2024 with a completion date of March 22, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award from the Defense Logistics Agency (DLA) is for the delivery of LANTUS SOLOSTAR 100 UNIT/ML 3ML, a specialty pharmaceutical product, to support military healthcare programs. The $4,418.71 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on February 21, 2025 with a completion date of February 24, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999...
This federal contract award is for the delivery of LANTUS SOLOSTAR 100 UNIT/ML 3ML pharmaceutical products to the Defense Logistics Agency (DLA). The $1,837.04 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of October 29, 2024 and was not set aside for any specific business category. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract...
This federal contract award is for the delivery of LANTUS SOLOSTAR 100 UNIT/ML 3ML pharmaceutical products to the Defense Logistics Agency (DLA). The $1,425.12 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a completion date of September 20, 2024 and was awarded on September 19, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between...
This federal contract award is for the delivery of LANTUS SOLOSTAR 100 UNIT/ML 3ML, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The $2,375.20 Firm Fixed Price Delivery Order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support...
This federal contract award is for the delivery of LANTUS SOLOSTAR 100 UNIT/ML 3ML, a prescription medical product, to the Defense Logistics Agency (DLA). The $1,317.50 firm-fixed-price Delivery Order was awarded to Amerisourcebergen Drug Corp, a pharmaceutical distribution company and subsidiary of Cencora, Inc. The award is associated with Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the...
This federal contract award is for the delivery of LANTUS SOLOSTAR 100 UNIT/ML 3ML pharmaceutical products to the Defense Logistics Agency (DLA). The $1,429.22 Firm Fixed Price delivery order was issued to the prime contractor, Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award is for the delivery of LANTUS SOLOSTAR 100 UNIT/ML 3ML pharmaceutical products to the Defense Logistics Agency (DLA). The $4,803.61 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award is for the delivery of LANTUS SOLOSTAR 100 UNIT/ML 3ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $7,648.23 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on March 7, 2025, with a period of performance through March 10, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB22FQVA7
    Delivery Order

This federal contract award is for the delivery of LANTUS SOLOSTAR 100 UNIT/ML 3ML, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $4,595.60 Firm Fixed Price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider.

The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This IDC encompasses critical medical commodities across multiple therapeutic areas and is set to run through November 2026. The contract does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 12:02 PM